Vancouver, British Columbia / TheNewswire / May 7th, 2018 - Radiant Health Care Inc. (the "Company" or "Radiant") announces the execution of binding agreements to acquire Tanta Therapeutics Inc. and a former Valeant Pharmaceuticals manufacturing facility, as well as the expansion of its management team with the appointment of Douglas Janzen to the Company’s Board of Directors.

Radiant is pleased to announce the appointment of Doug Janzen to the Board, effective immediately. As a former health care banker at Cormark Securities, Mr. Janzen has spent the past 15 years building and managing health care and pharmaceutical companies. His extensive operational and capital markets experience will be invaluable in helping lead the Company into the rapidly expanding medical cannabis markets, both domestic and international.

"We couldn't be more pleased with the addition of Doug Janzen to the Board.” stated Radiant's President and CEO, Brett Walker. "His pharmaceutical and banking experience will be invaluable to us in bringing our production capacity and intellectual property to the market in the most capital efficient manner."

The Company also announces that it has entered into a binding letter agreement with Tanta Therapeutics Inc. (“Tanta”), an Ontario-based pharmaceutical manufacturer and distributor of over-the-counter drugs and medical devices through its national chain-drug store customer base.  Tanta owns and operates a 25,000 square foot manufacturing and packaging facility featuring a Drug Establishment Site License, Medical Device Manufacturing Licenses, Natural Health Product Manufacturing License, ISO Certification and a GMP-licensed packaging room.

Radiant has also entered into an additional binding letter agreement with 10767034 Canada Inc. (“7034") which owns the exclusive right to acquire the former Valeant Pharmaceuticals plant in Montreal, Quebec. The acquisition of 7034 will allow Radiant to expand its cannabis derivative extraction operation through the acquisition of the former facility. The facility consists of 94,000 square feet of world-class pharmaceutical R&D laboratories, approved drug manufacturing, four gelatin capsule production lines, sterile packaging, and secure storage operations in which Radiant intends to launch Canada’s largest cannabis extraction and derivative products business.

Radiant's President and CEO, Brett Walker stated, "With the addition of 125,000 square feet of world-class, pharmaceutical manufacturing infrastructure, it will give us the scale to compete nationally, internationally, and long-term. We believe this scale, when combined with leading extraction and formulation intellectual property, will position us to become a leader in cannabis extract production and derivative product development and sale."

As previously announced (see news release dated February 7, 2018), Radiant has acquired 100% of the assets of cannabis patient, physician, and clinic software management company, Teal Valley Inc. ("Teal"). In recent months, Teal has relaunched under new management and has entered into revenue producing contracts, completing its first major clinic deployment in early May, 2018.

Concurrent with the anticipated completion of the above noted transactions and the Company's expected initial public offering on the Canadian Securities Exchange (the "CSE"), Radiant intends to change its name to "Tanta Cannabis Corp."

About Radiant

Radiant is a British Columbia based company focused on the healthcare sector. Currently, the principal business of the Company is the identification, evaluation, and acquisition of interests in healthcare assets and businesses, with a focus on the Canadian and emerging global medical cannabis sector.

About Teal

Teal is a private Ontario company engaged in the North American cannabis and clinic management sector through the development, licensing, and operation of its proprietary software platform and related services for clinics, physicians and clinical researchers.

On Behalf of the Board of Directors

Brett Walker

President & Chief Executive Officer

For further information, please contact:

Brett Walker

President & Chief Executive Officer (604) 366-7460

Forward-Looking Statements:

This news release includes certain statements forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995.  Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.  All statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future.  Often, but not always, forward looking statements can be identified by words such as "pro forma", "plans", "expects", "may", "should", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", "potential" or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved.  Such forward-looking statements include, among others, statements as to the ability of the Company to enter into definitive agreements in accordance with the Tanta LOI and the 7034 LOI and complete the transactions contemplated thereby (including, but not limited to, the acquisitions of the Tanta Facility and the Valeant Facility), the ability of the company to expand into the cannabis extraction and derivatives markets, the potential listing of the Company's securities on the CSE, the anticipated business plans and timing of future activities and the prospects of the success of the Company and Teal, including changes in management and changes to the Company's name.  Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company to, among other things, obtain the requisite approvals for the transactions and acquisitions contemplated by the Tanta LOI and the 7034 LOI and the listing of the Company's securities on a stock exchange, to enter into definitive agreements and acquire the Tanta Facility and the Valeant Facility, complete its anticipated business plans, and obtain the financing required to carry out its planned future activities .  Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the medical cannabis or pharmaceutical industry, may also adversely affect the future results or performance of the Company.  These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that those beliefs, plans, expectations, or intentions will prove to be accurate.  

Readers should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with Canadian securities regulators. These reports and the Company's public filings are available at www.sedar.com.